Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378 · View on ClinicalTrials.gov ↗

Study Summary

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

Interventions

  • DRUG RO7198457 intravenous (IV)
  • OTHER Observational group (no intervention)

Study Locations (20)

California

  • John Muir Clinical Research Center — Concord
  • The Oncology Institute of Hope and Innovation — Glendale
  • Marin Cancer Care — Greenbrae
  • St Joseph Hospital of Orange — Orange
  • Sansum Clinic — Santa Barbara

Florida

  • Boca Raton Regional Hospital — Boca Raton
  • Florida Cancer Specialist South — Fort Myers
  • Mayo Clinic Florida — Jacksonville
  • Florida Cancer Specialists — West Palm Beach

Minnesota

  • Allina Health — Minneapolis
  • Mayo Clinic Rochester — Rochester

New York

  • New York Oncology Hematology, P.C. — Albany
  • Weill Cornell Medical College — New York

Arizona

  • Mayo Clinic - Scottsdale — Scottsdale

Colorado

  • Rocky Mountain Cancer Centers - Denver Midtwon — Denver

Illinois

  • Cancer Care Center of Decatur, Cancer Care Specialists of IL — Decatur

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer — Indianapolis

Trial Details

FieldValue
Enrollment Target 327 participants
Start Date 2021-03-08
Est. Completion 2030-08
Phase Phase 2

Sponsor

BioNTech SE

123 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04486378

The ClinicalTrials.gov registry entry for NCT04486378 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech SE, which has 123 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Colorectal Cancer Stage II appearing as the primary indexed condition, and to 2 interventions — of which RO7198457 intravenous (IV) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04486378 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04486378 about?

NCT04486378 is a clinical study titled "A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer". This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

What is the current status of trial NCT04486378?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2021-03-08. Estimated completion is 2030-08.

What conditions does trial NCT04486378 study?

This clinical trial studies the following conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04486378?

The interventions under investigation include: RO7198457 intravenous (IV) (DRUG), Observational group (no intervention) (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04486378?

This trial is sponsored by BioNTech SE, which has 123 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04486378 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial